EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

New Glucosamine-Based TLR4 Agonists: Design, Synthesis, Mechanism of Action, and In Vivo Activity as Vaccine Adjuvants

Alessio Romerio, Nicole Gotri, Ana Rita Franco, Valentina Artusa, Mohammed Monsoor Shaik, Samuel T Pasco iD, Unai Atxabal, Alejandra Matamoros-Recio iD, Marina Mínguez-Toral iD, Juan Diego Zalamea, Antonio Franconetti iD, Nicola G A Abrescia iD und 4 weitere

Journal of Medicinal Chemistry · 2023

DOI: 10.1021/acs.jmedchem.2c01998 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2023. Verfasst von Alessio Romerio und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology and Biosciences, University of Milano-Bicocca, Piazza della Scienza, 2, 20126 Milano, Italy. Hauptthemen laut MEDLINE: Adjuvants, Vaccine, Toll-Like Receptor 4. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerio de Asuntos Econ?micos y Transformaci?n Digital, Gobierno de Espa?a, Agencia Estatal de Investigaci?n, European Regional Development Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We disclose here a panel of small-molecule TLR4 agonists (the FP20 series) whose structure is derived from previously developed TLR4 ligands (FP18 series). The new molecules have increased chemical stability and a shorter, more efficient, and scalable synthesis. The FP20 series showed selective activity as TLR4 agonists with a potency similar to FP18. Interestingly, despite the chemical similarity with the FP18 series, FP20 showed a different mechanism of action and immunofluorescence microscopy showed no NF-κB nor p-IRF-3 nuclear translocation but rather MAPK and NLRP3-dependent inflammasome activation. The computational studies related a 3D shape of FP20 series with agonist binding properties inside the MD-2 pocket. FP20 displayed a CMC value lower than 5 μM in water, and small unilamellar vesicle (SUV) formation was observed in the biological activity concentration range. FP20 showed no toxicity in mouse vaccination experiments with OVA antigen and induced IgG production, thus indicating a promising adjuvant activity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adjuvants, VaccineToll-Like Receptor 4MiceAnimalsAdjuvants, ImmunologicNF-kappa BVaccinationNLR Family, Pyrin Domain-Containing 3 ProteinInflammasomes

Substanzen

Adjuvants, VaccineToll-Like Receptor 4Adjuvants, ImmunologicNF-kappa BNLR Family, Pyrin Domain-Containing 3 ProteinInflammasomesTlr4 protein, mouse

Autor:innen und Institutionen

  • Department of Biotechnology and Biosciences, University of Milano-Bicocca, Piazza della Scienza, 2, 20126 Milano, Italy.
  • Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), 48160 Derio, Bizkaia, Spain.
  • Centro de Investigaciones Biológicas Margarita Salas CSIC, C/Ramiro de Maeztu, 9, 28040 Madrid, Spain.
  • Ikerbasque, Basque Foundation for Science, Plaza Euskadi 5, 48009 Bilbao, Bizkaia, Spain.
  • Department of Organic Chemistry, II Faculty of Science and Technology, EHU-UPV, 48940 Leioa, Spain.
  • Centro de Investigación Biomédica En Red de Enfermedades Respiratorias, 28029 Madrid, Spain.

ORCID-Profile: Samuel T Pasco, Alejandra Matamoros-Recio, Marina Mínguez-Toral, Antonio Franconetti, Nicola G A Abrescia, Jesus Jimenez-Barbero, Sonsoles Martín-Santamaría, Francesco Peri

Förderung

  • Ministerio de Asuntos Econ?micos y Transformaci?n Digital, Gobierno de Espa?a
  • Agencia Estatal de Investigaci?n
  • European Regional Development Fund
  • H2020 Marie Sklodowska-Curie Actions
  • Instituto de Salud Carlos III
  • Department of Biotechnology and Biosciences BtBs, University of Milano-Bicocca
  • National Interuniversity Consortium for Innovative Synthesis Methodologies and Processes CINMPIS

Zitieren

APA

Romerio, A., Gotri, N., Franco, A. R., Artusa, V., Shaik, M. M., Pasco, S. T., Atxabal, U., Matamoros-Recio, A., Mínguez-Toral, M., Zalamea, J. D., Franconetti, A., Abrescia, N. G. A., Jimenez-Barbero, J., Anguita, J., Martín-Santamaría, S., & Peri, F. (2023). New Glucosamine-Based TLR4 Agonists: Design, Synthesis, Mechanism of Action, and In Vivo Activity as Vaccine Adjuvants. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.2c01998

Vancouver

Romerio A, Gotri N, Franco AR, Artusa V, Shaik MM, Pasco ST, et al. New Glucosamine-Based TLR4 Agonists: Design, Synthesis, Mechanism of Action, and In Vivo Activity as Vaccine Adjuvants. Journal of Medicinal Chemistry. 2023. doi:10.1021/acs.jmedchem.2c01998

BibTeX
@article{Romerio2023,
  author = {Romerio, Alessio and Gotri, Nicole and Franco, Ana Rita and Artusa, Valentina and Shaik, Mohammed Monsoor and Pasco, Samuel T and Atxabal, Unai and Matamoros-Recio, Alejandra and Mínguez-Toral, Marina and Zalamea, Juan Diego and Franconetti, Antonio and Abrescia, Nicola G A and Jimenez-Barbero, Jesus and Anguita, Juan and Martín-Santamaría, Sonsoles and Peri, Francesco},
  title = {New Glucosamine-Based TLR4 Agonists: Design, Synthesis, Mechanism of Action, and In Vivo Activity as Vaccine Adjuvants},
  journal = {Journal of Medicinal Chemistry},
  year = {2023},
  doi = {10.1021/acs.jmedchem.2c01998}
}
Kostenlos starten →